• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

59.12 -0.46 (-0.77%)
Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
October 08, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
October 01, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
September 30, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma
September 25, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026
September 18, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
September 17, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
September 16, 2026
From Bristol Myers Squibb
Via Business Wire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via Investor Brand Network
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
September 08, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
August 29, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
August 13, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
August 10, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
July 30, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
July 20, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
July 13, 2026
From Bristol Myers Squibb
Via Business Wire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
June 24, 2026
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
June 24, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
June 18, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
June 17, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
June 08, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
June 02, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
June 01, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
June 01, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
May 29, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap